Method for the integration of foreign DNA into eukaryotic genomes

Abstract

Compositions and methods for introducing a DNA of interest into a genomic target site are provided. In particular, the methods and compositions involve the use of a combination of target sites for two site specific recombinases and expression of a chimeric recombinase with dual target site specificity. Thus, the compositions comprise novel site-specific recombinases with specificities to multiple target sites, and nucleotide sequences and expression cassettes encoding these recombinases or target sites. The methods involve transforming a eukaryotic cell having target sites for the novel recombinase with a DNA of interest that is flanked by corresponding target sites. Expression of the recombinase results in integration of the DNA of interest into the genome of the cell. The compositions and methods of the invention have use in the construction of stably transformed eukaryotic cells, and in particular, plant cells. The methods result in the efficient targeted genomic integration of DNA by site-specific recombination.

Description

FIELD OF THE INVENTION

The invention relates to the genetic modification of chromosomes. In particular, methods and compositions for the integration of DNA into a eukaryotic genome are provided.

BACKGROUND OF THE INVENTION

Several approaches have been used to integrate a DNA of interest into the genome of a plant. In the simplest method, DNA is introduced into a cell and randomly integrates into the genome through illegitimate recombination. One drawback to this method is that positional effects due to random integration make gene expression difficult to analyze.

As an alternative to illegitimate recombination, integration may be targeted to a particular site on the genome through the use of homologous recombination or site-specific recombination. In plants, where homologous recombination technology has not been developed, site-specific recombination is used to integrate a sequence of interest into an integration site that has been previously inserted into the plant host genome. If site-specific integration occurs by a single cross-over event between a chromosome and a circular extrachromosomal replicon, the entire replicon will be inserted into the chromosome. When insertion of the entire replicon is undesirable, a fragment of the replicon comprising the DNA of interest, flanked by target sites for a site-specific recombinase, may be introduced by a double reciprocal cross-over event, into a chromosome having an integration site corresponding to the target sites which flank the DNA of interest. In either case, integration is inefficient because it is reversible, that is, the integrated DNA may be excised by subsequent site-specific recombination between the target sites flanking the integrated DNA.

Several approaches have been taken to avoid excision of an integrated DNA. In one approach, expression of a site-specific recombinase, such as Cre or FLP, is temporally regulated. See O'Gorman et al. (1991) Science 251:1351-1355; Logie and Stewart (1995) Proc. Natl. Acad. Sci. 92:5940-5944; Zhang et al. (1996) Nuc. Acid Res. 24:543-548, Nichols et al. (1997) Mol. Endocinol. 11:950-961; and Feil et al. (1997) Biochem. Biophy. Res. Comm. 237:752-757; the contents of which are incorporated by reference. In these methods, the recombinase is briefly expressed, either transiently or inducibly, in order to allow integration. However, excision of the integrated DNA may occur before active recombinase disappears from the cell. Furthermore, intramolecular excision is kinetically favored over bi-molecular integration. Therefore, integrated DNA is inherently unstable in the presence of recombinase.

A second approach reduces excision of integrated DNA by using pairs of singly mutated target sites on both the chromosome and flanking the DNA of interest. See Albert et al. (1995) Plant J. 7:649-659; Schlake and Bode (1994) Biochemistry 33:12746-12751; O'Gorman et al. (1997) Proc. Natl. Acad. Sci. 94:14602-14607; and Araki et al. (1997) Nuc. Acid Res. 25:868-872; the contents of which are incorporated herein by reference. Recombination between singly mutated target sites results in doubly mutated target sites flanking the DNA inserted into the chromosome. The doubly mutated target sites are not well recognized by the recombinase. Thus, the inserted DNA is excised from the chromosome by a reverse reaction only at low levels. This system, however, has the disadvantage that the singly mutated target sites often do not act as efficient recombination substrates and thus the frequency of integration is reduced. In addition, transformants are unstable because excision may still occur, although at reduced frequency.

Accordingly, it is an object of the invention to provide efficient methods for site-specific integration of DNA into eukaryotic genomes which avoid subsequent excision reactions and other non-productive recombination reactions.

SUMMARY OF THE INVENTION

Compositions and methods for introducing a DNA of interest into a genomic integration site are provided. In particular, the methods and compositions involve the use of a combination of target sites for two distinctive site-specific recombinases, such as Cre and FLP, and expression of a chimeric recombinase with dual target site specificity. Thus, the compositions comprise novel site-specific recombinases with specificities to multiple target sites, and nucleotide sequences and expression cassettes encoding these recombinases or target sites. The methods involve transforming a eukaryotic cell having target sites for the novel recombinase with a DNA of interest that is flanked by corresponding target sites. Expression of either the novel chimeric recombinase or two site-specific recombinases in the eukaryotic cell results in integration of the DNA of interest into the genome. The compositions and methods of the invention have use in the construction of stably transformed eukaryotic cells, and in particular, plant cells. The methods result in the efficient targeted genomic integration of DNA by site-specific recombination.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 schematically represents plant transformation vectors, PHP13164 and PHP13147, for expression of moCRE recombinase and Cre:FLPm recombinase, respectively.

FIG. 2 graphically represents activation of GUS expression by FLPm or CRE:FLPm mediated excision of a sequence flanked by FRT sites that separates the ubiquitin promoter and the GUS open reading frame.

FIG. 3 graphically represents activation of GUS expression by CRE:FLPm mediated excision of a sequence flanked by loxP sites that separates the ubiquitin promoter and the GUS open reading frame.

DETAILED DESCRIPTION OF THE INVENTION

Compositions and methods for site-specific integration of DNA into predetermined genomic integration sites in a host genome are provided. The invention provides for the use of chimeric recombinases that catalyze site-specific recombination between target sites that originate from different site-specific recombination systems. Such a dual function chimeric recombinase ensures that the two ends of foreign DNA do not ligate with each other, but instead, recombine with their cognate partner target sites residing in the genomic DNA. The methods facilitate the directional targeting of desired genes and nucleotide sequences into corresponding integration sites previously introduced into the genome.

In the methods of the invention, a combination of target sites for two site-specific recombinases are introduced into the genome of an organism of interest, establishing an integration site for insertion of nucleotide sequences of interest. For the purposes of the invention, an integration site will comprise flanking target sites where the target sites correspond to the recombination sites for two distinctive site-specific recombinases. These recombination or target sites may flank other nucleotide sequences or may be contiguous. Methods for the production of transgenic plants containing specific recombination sites integrated in the plant genome are described in co-pending provisional application, serial No. 60/065,627, entitled Compositions and Methods for Genetic Modification of Plants, filed Nov. 18, 1997, and herein incorporated by reference. Once a stable plant or cultured tissue is established, a transfer cassette comprising a DNA of interest, flanked by target sites corresponding to those of the genomic integration site, is introduced into the stably transformed plant or tissues in the presence of a chimeric recombinase with specificities to each of the target sites. Alternatively, two distinct recombinases corresponding to the target sites may be present in the cell in lieu of a chimeric recombinase. This process results in exchange of the nucleotide sequences between the two identical target sites of the genomic integration site and the transfer cassette.

Thus, the invention provides a method for integrating a DNA of interest into the genome of a eukaryotic cell, comprising:

a) transforming said cell with a transfer cassette comprising said DNA, wherein said DNA is flanked by a target site for a first site-specific recombinase and a target site for a second site-specific recombinase, and said genome contains an integration site comprising target sites corresponding to said target sites flanking said DNA, and

b) providing in said cell a recombinant protein comprising said first recombinase fused in frame with said second recombinase.

The invention further provides a method for integrating a DNA of interest into the genome of a eukaryotic cell, comprising:

a) transforming said cell with a transfer cassette comprising said DNA, wherein said DNA is flanked by a target site for a first site-specific recombinase and a target site for a second site-specific recombinase, and said genome contains an integration site comprising target sites corresponding to said target sites flanking said DNA; and

b) providing in said cell said first recombinase and said second recombinase.

By “site-specific recombinase” is meant any enzyme that catalyzes conservative site-specific recombination between its corresponding recombination sites. For reviews of site-specific recombinases, see Sauer (1994) Current Opinion in Biotechnology 5:521-527, and Sadowski (1993) FASEB 7:760-767, the contents of which are incorporated herein by reference.

The first and second site-specific recombinases may be full length recombinases and/or active fragments or derivatives thereof. Site-specific recombinases useful for creating the chimeric recombinases of the invention, include recombinases from the integrase family, derivatives thereof, and any other naturally occurring or recombinantly produced enzyme or derivative thereof, that catalyzes conservative site-specific recombination between specified DNA sites. The integrase family of recombinases has over thirty members and includes FLP, Cre, Int and R. Preferably, the recombinases do not require cofactors or a supercoiled substrate. Most preferably the recombinases are Cre and FLP. The bacteriophage P1 loxP-Cre and the Saccharomyces 2μ plasmid FRT/FLP site-specific recombinations systems have been extensively studied and their uses are well known to those skilled in the art. Cre and FLP are known to function in a variety of organisms, including bacteria, yeast, Drosophila, mammals and monocotyledonous and dicotyledonous plants. In addition these recombinases do not require auxiliary factors to function.

The site-specific recombinases and sequences encoding them that are used in the methods and compositions of the invention may be variants of naturally occurring recombinases and the genes encoding them. The term “conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or conservatively modified variants of the amino acid sequences. Because of the degeneracy of the genetic code, a large number of fuinctionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations” and represent one species of conservatively modified variation. One of ordinary skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Thus, any number of amino acid residues selected from the group of integers consisting of from 1 to 15 can be so altered. Thus, for example, 1, 2, 3, 4, 5, 7, or 10 alterations can be made. Conservatively modified variants typically provide similar biological activity as the unmodified polypeptide sequence from which they are derived. For example, substrate specificity, enzyme activity, or ligand/receptor binding is generally at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the native protein for its native substrate. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

1) Alanine (A), Serine (S), Threonine (T);

2) Aspartic acid (D), Glutamic acid (E);

3) Asparagine (N), Glutamine (Q);

4) Arginine (R), Lysine (K);

5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and

6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

See Creighton (1984) Proteins, W. H. Freeman and Company.

Rather than use full length recombinases, fuinctional fragments of site-specific recombinases may be used in the methods and compositions of the invention. Functional fragments of site-specific recombinases can be identified using a variety of techniques. For example, functional fragments of the FLP protein may be identified by their ability, upon introduction to cells containing appropriate FRT substrates, to catalyze site-specific recombination and result in the excision of an assayable marker gene.

A general approach of such functional analysis involves subcloning DNA fragments of a genomic clone, cDNA clone or synthesized gene sequence into an expression vector, introducing the expression vector into a heterologous host, and screening to detect the product of recombination (i.e. using restriction analysis to verify the product of recombination at the nucleic acid level, or relying on an assay system for recombination as described above). Methods for generating fragments of a cDNA or genomic clone are well known. Variants of an isolated DNA encoding a site-specific recombinase can be produced by deleting, adding and/or substituting nucleotides. Such variants can be obtained, for example, by oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like. See, for example, Ausubel, Current Protocols In Molecular Biology, Wiley Interscience (1990) pages 8.0.3-8.5.9, and McPherson (ed.), Directed Mutagenesis: A Practical Approach, (IRL Press, 1991).

The dual function recombinant proteins of the invention comprise a first site-specific recombinase fused in frame with a second site-specific recombinase. It will be recognized that in the methods of invention, the recombinases comprising the chimeric recombinase must correspond to the target sites of the transformed organism and the targeting cassette. That is, if FRT and loxP sites are utilized, a chimeric FLP:Cre recombinase will be needed.

The open reading frames encoding the first and second recombinases may be directly fused to each other or may be joined by a linker that maintains the correct reading frame of the chimeric recombinase. It is understood that the recombinases may be fused amino to carboxy terminus, amino to amino terminus, or carboxy to amino terminus.

Genes encoding chimeric site-specific recombinases and recombination sites can be made using standard recombinant methods, synthetic techniques, or combinations thereof Use of cloning vectors, expression vectors, adapters, and linkers is well known in the art and can be found in such references as Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor, N.Y., 1989). A variety of strategies are available for ligating fragments of DNA, the choice of which depends on the nature of the termini of the DNA fragments and which choices can be readily made by those of skill in the art. The FLP recombinase gene from yeast ( Saccharomyces cerevisiae ) is commercially available in plasmid pOG44 from Stratagene Cloning Systems (11011 North Torrey Pines Road, La Jolla, Calif. 92037). For a description of the FLP gene and various nucleic acids see, for example, Stratagene Cloning Systems, Catalogs 1995, 1996, 1997 (La Jolla, Calif.); and, Amersham Life Sciences, Inc, Catalog '97 (Arlington Heights, Ill.). Similarly, the sequences of many other site specific recombinases and their cognate recombination sites are publicly or commercially available. Genes encoding FLP and Cre can also be obtained, for example, by synthesizing the genes with mutually priming long oligonucleotides. See, for example, Ausubel et al. (eds.), Current Protocols In Molecular Biology, pages 8.2.8 to 8.2.13, Wiley Interscience (1990). Also, see Wosniak et al. (1987) Gene 60:115. Moreover, current techniques using the polymerase chain reaction provide the ability to synthesize genes as large as 1.8 kilobases in length (Adang et al. (1993) Plant Mol. Biol. 21:1 131; Bombat et al. (1993) PCR Methods and Applications 2:266).

When the nucleic acid is prepared or altered synthetically, advantage can be taken of known codon preferences of the intended host where the nucleic acid is to be expressed. For example, although nucleic acid sequences of the present invention may be expressed in both monocotyledonous and dicotyledonous plant species, sequences can be modified to account for the specific codon preferences and GC content preferences of monocotyledons or dicotyledons as these preferences have been shown to differ (Murray et al. (1989) Nucl. Acids Res. 17:477-498; and Campbell et al. (1990) Plant Physiol. 92:1). Thus, the maize preferred codon for a particular amino acid may be derived from known gene sequences from maize. Maize codon usage for 28 genes from maize plants are listed in Table 4 of Murray et al., supra.

Examples of genes encoding recombinases, using maize preferred codons include, FLPm, described in co-pending application Ser. No. 08/972,258; the contents of which are incorporated herein by reference, and moCre, shown in SEQ. ID NOS. 1 and 2. FLPm is derived from the Saccharomyces 2μ plasmid FLP recombinase, but is encoded by a nucleic acid sequence utilizing maize-preferred codons. While the FLPm nucleic acid sequence includes preferred codons for expression of amino acids in maize, it is understood that a useful sequence may contain codons occurring in maize with less than the highest reported maize codon frequencies. Examples of nucleic acids encoding chimeric recombinases include Cre:FLPm (SEQ. ID NO. 4), moCre:FLPm (SEQ. ID NO. 5), Cre:FLP (SEQ. ID NO. 7) and FLPm:Cre (SEQ. ID NO. 8).

The invention also provides expression cassettes containing a nucleic acid sequence encoding a chimeric site-specific recombinase, operably linked to a promoter that drives expression in a eukaryotic cell. Preferably the promoter is a plant promoter. For example, the plant expression vector PHP13147, shown in FIG. 1 , contains an expression cassette for Cre:FLPm, wherein the gene encoding the chimeric recombinase is operably linked to a ubiquitin promoter. As used herein “operably linked” includes reference to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

As used herein “promoter” includes reference to a region of DNA upstream from the start of transcription and involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A “plant promoter” is a promoter capable of initiating transcription in plant cells. Exemplary plant promoters include, but are not limited to, those that are obtained from plants, plant viruses, and bacteria genes that are expressed in plant cells such as those of Agrobacterium or Rhizobium. Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of a sequence encoding a site-specific recombinase. The promoter may be constitutive, inducible or tissue specific.

Many different constitutive promoters can be utilized in the instant invention. Exemplary constitutive promoters include the promoters from plant viruses such as the 35S promoter from CaMV (Odell et al. (1985) Nature 313:810-812) and the promoters from such gene as rice actin (McElroy et al. (1990) Plant Cell 2:163-171), ubiquitin (Christensen et al. (1989) Plant Mol. Biol. 12:619-632 and Christensen et al. (1992) Plant Mol. Biol. 18:675-689), pEMU (Last et al. (1991) Theor. Appl. Genet. 81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-2730), maize H3 histone (Lepetit et al. (1992) Mol. Gen. Genet. 231: 276-285 and Atanassova et al. (1992) Plant Journal 2(3):291-300); the 1′- or 2′- promoter derived from T-DNA of Agrobacterium tumefaciens, the Smas promoter, the cinnamyl alcohol dehydrogenase promoter (U.S. Pat. No. 5,683,439), the Nos promoter, the Pemu promoter, the rubisco promoter, the GRP1-8 promoter, and other transcription initiation regions from various plant genes known to those of skill. The ALS promoter, a XbaI/NcoI fragment 5-prime to the Brassica napus ALS3 structural gene (or a nucleotide sequence that has substantial sequence similarity to said XbaI/NcoI fragment), represents a particularly useful constitutive promoter. (See co-pending Pioneer Hi-Bred International U.S. patent application Ser. No. 08/409,297, the contents of which are incorporated by reference).

A variety of inducible promoters can be used in the instant invention. See Ward et al. (1993) Plant Mol. Biol. 22:361-366. Exemplary inducible promoters include that from the ACE1 system which responds to copper (Mett et al. (1993) PNAS 90:4567-4571); In2 gene from maize which responds to benzenesulfonamide herbicide safeners (Hershey et al. (1991) Mol. Gen. Genetics 227:229-237 and Gatz et al. (1994) Mol. Gen. Genetics 243:32-38), the Adh1 promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPDK promoter which is inducible by light; or Tet repressor from Tn10 (Gatz et al. (1991) Mol. Gen. Genet. 227:229-237. A particularly preferred inducible promoter is a promoter that responds to an inducing agent to which plants do not normally respond. An exemplary inducible promoter is the inducible promoter from a steroid hormone gene the transcriptional activity of which is induced by a glucocorticosteroid hormone (Schena et al. (1991) Proc. Natl. Acad. Sci. U.S.A. 88:10421).

Examples of promoters under developmental control include promoters that initiate transcription only, or preferentially, in certain tissues, such as leaves, roots, fruit, seeds, or flowers. The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

The chimeric recombinase must be expressed in the plant cell in order for integration of the DNA of interest into the host chromosome. Accordingly, the expression cassette encoding the site-specific recombinase may be supplied in cis to the DNA of interest; in trans on a host chromosome or extrachromosomal replicon; or may be transferred to the host and transiently expressed near to the time that recombination is desired.

The compositions of the invention include transfer cassettes comprising nucleotide sequences encoding the chimeric recombinases of the invention. By transfer cassette is meant any nucleotide sequence that may be used to transform a cell of interest. For example, the transfer cassette may be an independent replicon such as a plasmid, shuttle vector, Ti plasmid, viral vector or the like. Alternatively, the transfer cassette could be a nucleic acid that is not capable of independent replication, yet could be transferred into an organism of interest by a variety of transformation protocols, such as particle bombardment, electroporation, and the like. Thus, the invention provides a transfer cassette comprising a nucleotide sequence encoding a recombinant protein comprising a first site-specific recombinase fused in frame with a second site-specific recombinase, wherein said nucleotide sequence is operably linked to a promoter that drives expression in a eukaryotic cell.

In the compositions and methods of the invention, the DNA of interest is flanked by target sites for two distinct site-specific recombinases. By “flanked by” is meant that the recombination or target sites may be directly contiguous with the DNA of interest, or there may be one or more intervening sequences present between one or both ends of the DNA of interest and the site specific recombination sites. Intervening sequences of particular interest would include linkers, adapters, selectable markers and/or other sites which aid in vector construction or analysis and expression cassette for a gene of interest. Target sites for site-specific recombinases are known to those skilled in the art and are discussed in co-pending provisional application No. 60/065,613. Examples of target sites include, but are not limited to FRT, FRT1, FRT5, FRT6, FRT7, other FRT mutants, loxP, loxP mutants, and the like. See, for example, Schlake and Bode (1994) Biochemistry 33:12746-12751; Huang et al. (1991) Nucleic Acids Research 19:443-448; Sadowski (1995) In Progress in Nucleic Acid Research and Molecular Biology 51:53-91; Cox (1989) In Mobile DNA, Berg and Howe (eds) American Society of Microbiology, Washington D.C., pp. 116-670, Dixon et al. (1995) Mol. Microbio. 18:449-458; Umlauf and Cox (1988) EMBO J. 7:1845-1852; Buchholz et al. (1996) Nuc. Acids Res. 24:3118-3119; Kilby et al. (1993) Trends Genet. 9:413-42 1: Rossant and Geagy (1995) Nat. Med. 1: 592-594, Lox Albert et al. (1995) Plant J. 7:649-659: Bayley et al. (1992) Plant Mol. Biol. 18:353-361; Odell et al. (1990) Mol. Gen. Genet. 223:369-378; and Dale and Ow (1991) Proc. Natl. Acad. Sci. USA 88:10558-105620; Qui et al. (1994) Proc. Natl. Acad. Sci. USA 91:1706-171 0; Stuurman et al. (1996) Plant Mol. Biol. 32:901-913; and Dale et al. (1990) Gene 91:79-85; all of which are herein incorporated by reference.

By “target site for a site-specific recombinase” is meant a DNA sequence that is recognized by a particular site-specific recombinase. A variety of recombination sites are known to those skilled in the art and may be used in the methods and compositions of the invention. The site may have the sequence of the cognate site for a given recombinase, or may be modified, so long as it is capable of acting as a recombination site. The site may be contain the minimal sequences necessary for recombination, or it may contain additional sequences that enhance recombination. Examples of recombination sites for use in the invention are known in the art and include FRT and loxp sites (See, for example, Schlake et al. (1994) Biochemistry 33:12746-1275 1; Huang et al. (1991) Nucleic Acids Research 19:443-448; Sadowski, Paul D. (1995) In Progress in Nucleic Acid Research and Molecular Biology 51: 53-91; Cox, Michael M. (1989) In Mobile DNA, Berg and Howe (eds) American Society of Microbiology, Washington D.C., pp. 116-670; Dixon et al. (1995) Mol. Microbio. 18.449-458; Umlaufet et al. (1988) EMBO J. 7:1845-1852; Buchholz et al. (1996) Nuc. Acids Res. 24:3118-3119, Kilby et al. (1993) Trends Genet. 9:413-421: Rossant et al. (1995) Nat. Med. 1: 592-594, Lox Albert et al. (1995) Plant J. 7:649-659: Bayley et al. (1992) Plant Mol. Biol. 18:353-361; Odell et al. (1990) Mol. Gen. Genet. 223:369-378, and Dale et al. (1991) Proc. Natl. Acad. Sci. USA 88:10558-105620; Qui et al. (1994) Proc. Natl. Acad. Sci. USA 91:1706-1710, Stuurman et al. (1996) Plant Mol. Biol. 32:901-913; Hartley et al. (1980) Nature 286: 860-864; Sauer (1994) Current Opinion in Biotechnology 5:521-527; and Dale et al. (1990) Gene 91:79-85; all of which are herein incorporated by reference.)

Each loxP and FRT site contains two 13 base pair inverted repeats which flank an 8 base pair spacer. The FRT site contains an additional non-essential 13 base pair repeat. The sequences of the loxP and FRT sites have been described in many publications. A minimal FRT site (SEQ ID NO: 10)comprising two 13 base pair repeats, separated by an 8 base spacer, is:

5′-GAAGTTCCTATTC[TCTAGAAA]GTATAGGAACTTC3′

wherein the nucleotides within the brackets indicate the spacer region. The nucleotides in the spacer region can be replaced with a combination of nucleotides, so long as the two 13-base repeats are separated by eight nucleotides. FLP is a conservative, site-specific recombinase, capable of catalyzing inversion of a nucleic acid sequence positioned between two inversely oriented FRTs; recombination between two molecules each containing a FRT site; and excision between FRT sites. The core region is not symmetrical, and its asymmetry dictates the directionality of the reaction. Recombination between inverted FRT sites causes inversion of a DNA sequence between them, whereas recombination between directly oriented sites leads to excision of the DNA between them.

Nucleotide sequences containing a DNA of interest flanked by target sites, transfer cassettes for two distinct site-specific recombinases and vectors carrying these sequences may be constructed using standard molecular biology techniques. See, for example, Sambrook et al. (eds.) Molecular Cloning: A Laboratory Manual, Second Edition, (Cold Spring Harbor Laboratory Press, cold Spring Harbor, N.Y. 1989).

Techniques for transforming a wide variety of eukaryotic cells, including higher plant species are well known and described in the technical, scientific, and patent literature. See, for example, Weising et al. (1988) Ann. Rev. Genet. 22: 421-477. These methods are useful for transforming a plant cell with the chimeric recombinase expression cassettes of the invention and DNAs of interest flanked by target sites for the chimeric recombinase. The expression cassette encoding the site-specific recombinase may be present in the plant genome prior to transformation of the DNA of interest, or may be transformed into the plant around the time of transformation with the T-DNA to the plant cell so that it will be transiently expressed. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation, PEG poration, particle bombardment, silicon fiber delivery, or microinjection of plant cell protoplasts or embryogenic callus.

Agrobacterium tumefaciens -meditated transformation techniques are well described in the scientific literature. See, for example Horsch et al, Science 233: 496-498 (1984), Fraley et al. (1983) Proc. Natl. Acad. Sci. 80:4803 and Kado, (1991), Crit. Rev. Plant Sci. 10:1. Descriptions of the Agrobacterium vector systems and methods for Agrobacterium-mediated gene transfer are provide in Gruber et al., supra, Miki, et al., supra; and Moloney et al. (1989), Plant Cell Reports 8:238. Although Agrobacterium is useful primarily in dicots, certain monocots can be transformed by Agrobacterium. For instance, Agrobacteriurm transformation of maize is described in U.S. Pat. No. 5,550,318. Other methods of agroinfection include Agrobacterium rhizogenes -mediated transformation (see, e.g., Lichtenstein and Fuller In: Genetic Engineering, vol. 6, P W J Rigby, Ed., London, Academic Press, 1987; and Lichtenstein, C. P., and Draper, J,. In: DNA Cloning, Vol. II, D. M. Glover, Ed., Oxford, IRI Press, 1985), Application PCT/US87/02512 (WO 88/02405 published Apr. 7, 1988) describes the use of A. rhizogenes strain A4 and its Ri plasmid along with A. tumefaciens vectors pARC8 or pARC16.

Optimized methods and vectors for Agrobacterium-mediated transformation of plants in the family Graminae, such as rice and maize have been described by Heath et al. (1997) Mol. Plant-Microbe Interact. 10:221-227; Hiei et al. (1994) Plant J. 6:271-282 and Ishida et al. (1996) Nat. Biotech. 14:745-750, the contents of which are incorporated herein by reference. The efficiency of maize transformation is affected by a variety of factors including the types and stages of tissue infected, the concentration of Agrobacterizum, the tissue culture media, the Ti vectors and the maize genotype. Super binary vectors carrying the vir genes of Agrobacterium strains A281 and A348 are useful for high efficiency transformation of monocots.

The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski et al. (1984) Embo J. 3: 2717-2722. Electroporation techniques are described in Fromm et al. (1985) Proc. Natl. Acad. Sci. 82: 5824. Ballistic transformation techniques are described in Klein et al. (1987) Nature 327: 70-73.

Viral means of introducing DNA into mammalian cells are known in the art. In particular, a number of vector systems are known for the introduction of foreign or native genes into mammalian cells. These include SV40 virus (See, e.g., Okayama et al. (1985) Molec. Cell Biol. 5:1136-1142), Bovine papilloma virus (See, e.g., DiMaio et al. (1982) Proc. Natl. Acad. Sci. USA 79:4030-4034); adenovirus (See, e.g., Morin et al. (1987) Proc. Natl. Acad. Sci. USA 84:4626; Yifan et al. (1995) Proc. Natl. Acad. Sci. USA 92:1401-1405; Yang et al. (1996) Gene Ther. 3:137-144; Tripathy et al. (1996) Nat. Med. 2:545-550; Quantin et al. (1992) Proc. Natl. Acad. Sci. USA 89:2581-2584; Rosenfeld et al. (1991) Science 252:431-434; Wagner (1992) Proc. Natl. Acad. Sci. USA 89:6099-6103; Curiel et al. (1992) Human Gene Therapy 3:147-154; Curiel (1991) Proc. Natl. Acad. Sci. USA 88:8850-8854; LeGal LaSalle et al. (1993) Science 259:590-599); Kass-Eisler et al. (1993) Proc. Natl. Acad. Sci. USA 90:11498-11502), adeno-associated virus (See, e.g., Muzyczka et al. (1994) J. Clin. Invest. 94:13 5 1; Xiao et al. (1996) J. Virol. 70:8098-8108); herpes simplex virus (See, e.g., Geller et al. (1988) Science 241:1667; Huard et al. (1995) Gene Therapy 2:385-392, U.S. Pat. No. 5,501,979), retrovirus-based vectors (See, for example, Curran et al. (1982) J. Virol. 44:674-682; Gazit et al. (1986) J. Virol. 60: 19-28; Miller, A. D. (1992) Curr. Top. Microbiol. Immunol. 158:1-24; Cavanaugh et al. (1994) Proc. Natl. Acad. Sci. USA 91:7071-7075; Smith et al. (1990) Molecular and Cellular Biology 10:3268-3271); herein incorporated by reference. See also, Wu et al. (1991) J. Biol. Chem. 266:14338-14342, Wu et al. (1988) J. Biol Chem. 263:14621-14624; Wu et al. (1989) J. Biol Chem. 264:16985-16987; Zenke et al. (1990) Proc. Natl. Acad. Sci. USA 87:3655-3659; Wagner et al. (1990) Proc. Natl. Acad. Sci. USA 87:3410-3414.

DNA can also be introduced into plants by direct DNA transfer into pollen as described by Zhou et al. (1983) Methods in Enzymology, 101:433; D. Hess, (1987) Intern Rev. Cytol., 107:367; Luo et al. (1988) Plane Mol. Biol. Reporter 6:165. Expression of polypeptide coding genes can be obtained by injection of the DNA into reproductive organs of a plant as described by Pena et al. (1987) Nature 325:274. DNA can also be injected directly into the cells of immature embryos and the rehydration of desiccated embryos as described by Neuhaus et al. (1987) Theor. Appl. Genet. 75:30; and Benbrook et al. (1986) Proceedings Bio Expo, Butterworth, Stoneham, Mass., pp. 27-54. A variety of plant viruses that can be employed as vectors are known in the art and include cauliflower mosaic virus (CaMV), geminivirus, brome mosaic virus, and tobacco mosaic virus.

Plants cells stably transformed with a chimeric recombinase expression cassette can be regenerated, e.g., from single cells, callus tissue or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues, and organs from almost any plant can be successfully cultured to regenerate an entire plant. Plant regeneration from cultured protoplasts is described in Evans et al. (1983) Protoplasis Isolation and Culture, Handbook of Plant Cell Culture, Macmillilan Publishing Company, New York, pp. 124-176; and Binding (1985) Regeneration of Plants, Plant Protoplasts, CRC Press, Boca Raton, pp. 21-73.

The regeneration of plants containing the recombinant genes can be achieved as described by Horsch et al. (1985) Science, 227:1229-1231. In this procedure, transformants are grown in the presence of a selection agent and in a medium that induces the regeneration of shoots in the plant species being transformed as described by Fraley et al. (1983) Proc. Natl. Acad. Sci. USA 80:4803. This procedure typically produces shoots within two to four weeks and these transformant shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth. Transgenic plants of the present invention may be fertile or sterile.

Regeneration can also be obtained from plant callus, explants, organs, or parts thereof Such regeneration techniques are described generally in Klee et al. (1987) Ann. Rev. of Plant Phys. 38: 467-486. The regeneration of plants from either single plant protoplasts or various explants is well known in the art. See, for example, Methods for Plant Molecular Biology, A. Weissbach and H. Weissbach, eds., Academic Press, Inc., San Diego, Calif. (1988). This regeneration and growth process includes the steps of selection of transformant cells and shoots, rooting the transformant shoots and growth of the plantlets in soil. For maize cell culture and regeneration see generally, The Maize Handbook, Freeling and Walbot, Eds., Springer, New York (1994); Corn and Corn Improvement, 3rd edition, Sprague and Dudley Eds., American Society of Agronomy, Madison, Wis. (1988).

One of skill will recognize that after a DNA, such as a chimeric recombinase expression cassette or target site for a chimeric recombinase is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

The methods and compositions of the invention are useful to integrate a DNA of interest into the genome of any host cell, including any plant host. As used herein, the term “plant” includes reference to whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. Plant cell, as used herein includes, without limitation, seeds suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores. The class of plants which can be used in the methods of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants. A particularly preferred monocot is maize. Other monocots of particular interest include wheat, rice, barley, sorghum and rye. Dicots of particular interest include soybean, Brassica, sunflower, alfalfa, and safflower.

Because of the use of the chimeric site-specific recombinases and target sites provided herein, the cells transformed by the methods of the invention may be distinguishable from other transformation methods as the modified cells of the invention will contain nucleotide sequences of interest inserted into the genome flanked by target sites for distinct recombinases.

The following examples are offered by way of illustration not by way of limitation.

EXPERIMENTAL

EXAMPLE 1

Construction of Vectors Containing a DNA of Interest Flanked By Target Sites For a Chimeric Site-Specific Recombinase

DNA fragments containing a DNA of interest flanked by loxP and FRT target sites are constructed either by synthesizing, annealing and ligating complementary oligonucleotides or by creating primers for PCR amplification of a DNA of interest with containing the loxp and bRT sites in addition to restriction sites useful for cloning into a vector of choice.

For example, long PCR primers may be designed wherein the 3′ end of the primer hybridizes to the 5′ end of the DNA of interest and the 5′ end of the primers further contain loxP or FRT sites and useful cloning sites. The resulting PCR product is digested with the appropriate restriction enzyme and inserted into an appropriate vector,

EXAMPLE 2

Excision of FRT Site by FLPm and the Cre:FLPm Chimeric Recombinase

A transfer cassette encoding a Cre-FLPm chimeric recombinase was transformed into plant cells having an expression cassette encoding GUS driven by the ubiquitin promoter, wherein a sequence flanked by either identical FRT or loxP sites interrupted the GUS open reading frame. FIGS. 2 and 3 show that the Cre-FLPm chimeric recombinase is functional independently at either the FRT site or the loxP site, as measured by the ability to activate GUS activity following excision of sequences between two identical target sites, thereby bringing GUS activity under the control of the ubiquitin promoter.

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the aft to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

11 1 343 PRT Artificial Sequence Description of Artificial Sequence Cre protein from Bacteriophage P1 with maize preferred codons (moCRE) 1Met Ser Asn Leu Leu Thr Val His Gln Asn Leu Pro Ala Leu Pro Val 1 5 10 15Asp Ala Thr Ser Asp Glu Val Arg Lys Asn Leu Met Asp Met Phe Arg 20 25 30Asp Arg Gln Ala Phe Ser Glu His Thr Trp Lys Met Leu Leu Ser Val 35 40 45Cys Arg Ser Trp Ala Ala Trp Cys Lys Leu Asn Asn Arg Lys Trp Phe 50 55 60Pro Ala Glu Pro Glu Asp Val Arg Asp Tyr Leu Leu Tyr Leu Gln Ala 65 70 75 80Arg Gly Leu Ala Val Lys Thr Ile Gln Gln His Leu Gly Gln Leu Asn 85 90 95Met Leu His Arg Arg Ser Gly Leu Pro Arg Pro Ser Asp Ser Asn Ala 100 105 110Val Ser Leu Val Met Arg Arg Ile Arg Lys Glu Asn Val Asp Ala Gly 115 120 125Glu Arg Ala Lys Gln Ala Leu Ala Phe Glu Arg Thr Asp Phe Asp Gln 130 135 140Val Arg Ser Leu Met Glu Asn Ser Asp Arg Cys Gln Asp Ile Arg Asn145 150 155 160Leu Ala Phe Leu Gly Ile Ala Tyr Asn Thr Leu Leu Arg Ile Ala Glu 165 170 175Ile Ala Arg Ile Arg Val Lys Asp Ile Ser Arg Thr Asp Gly Gly Arg 180 185 190Met Leu Ile His Ile Gly Arg Thr Lys Thr Leu Val Ser Thr Ala Gly 195 200 205Val Glu Lys Ala Leu Ser Leu Gly Val Thr Lys Leu Val Glu Arg Trp 210 215 220Ile Ser Val Ser Gly Val Ala Asp Asp Pro Asn Asn Tyr Leu Phe Cys225 230 235 240Arg Val Arg Lys Asn Gly Val Ala Ala Pro Ser Ala Thr Ser Gln Leu 245 250 255Ser Thr Arg Ala Leu Glu Gly Ile Phe Glu Ala Thr His Arg Leu Ile 260 265 270Tyr Gly Ala Lys Asp Asp Ser Gly Gln Arg Tyr Leu Ala Trp Ser Gly 275 280 285His Ser Ala Arg Val Gly Ala Ala Arg Asp Met Ala Arg Ala Gly Val 290 295 300Ser Ile Pro Glu Ile Met Gln Ala Gly Gly Trp Thr Asn Val Asn Ile305 310 315 320Val Met Asn Tyr Ile Arg Asn Leu Asp Ser Glu Thr Gly Ala Met Val 325 330 335Arg Leu Leu Glu Asp Gly Asp 340 2 1032 DNA Artificial Sequence Description of Artificial Sequence Nucleotide sequence encoding Cre protein from Bacteriophage P1, maize preferred codons (moCRE) 2atgtccaacc tgctcacggt tcaccagaac cttccggctc ttccagtgga cgcgacgtcc 60gatgaagtca ggaagaacct catggacatg ttccgcgaca ggcaagcgtt cagcgagcac 120acctggaaga tgctgctctc cgtctgccgc tcctgggctg catggtgcaa gctgaacaac 180aggaagtggt tccccgctga gcccgaggac gtgagggatt accttctgta cctgcaagct 240cgcgggctgg cagtgaagac catccagcaa caccttggac aactgaacat gcttcacagg 300cgctccggcc tcccgcgccc cagcgactcg aacgccgtga gcctcgtcat gcgccgcatc 360aggaaggaaa acgtcgatgc cggcgaaagg gcaaagcagg ccctcgcgtt cgagaggacc 420gatttcgacc aggtccgcag cctgatggag aacagcgaca ggtgccagga cattaggaac 480ctggcgttcc tcggaattgc atacaacacg ctcctcagga tcgcggaaat tgcccgcatt 540cgcgtgaagg acattagccg caccgacggc ggcaggatgc ttatccacat tggcaggacc 600aagacgctcg tttccaccgc aggcgtcgaa aaggccctca gcctcggagt gaccaagctc 660gtcgaacgct ggatctccgt gtccggcgtc gcggacgacc caaacaacta cctcttctgc 720cgcgtccgca agaacggggt ggctgcccct agcgccacca gccaactcag cacgagggcc 780ttggaaggta ttttcgaggc cacccaccgc ctgatctacg gcgcgaagga tgacagcggt 840caacgctacc tcgcatggtc cgggcactcc gcccgcgttg gagctgctag ggacatggcc 900cgcgccggtg tttccatccc cgaaatcatg caggcgggtg gatggacgaa cgtgaacatt 960gtcatgaact acattcgcaa ccttgacagc gagacgggcg caatggttcg cctcctggaa 1020gatggtgact ga 1032 3 781 PRT Artificial Sequence Description of Artificial Sequence CreFLPm polypeptide, Cre from Bacteriophage P1 and FLP from Saccharomyces with maize preferred codons 3Met Ala Asn Leu Leu Thr Val His Gln Asn Leu Pro Ala Leu Pro Val 1 5 10 15Asp Ala Thr Ser Asp Glu Val Arg Lys Asn Leu Met Asp Met Phe Arg 20 25 30Asp Arg Gln Ala Phe Ser Glu His Thr Trp Lys Met Leu Leu Ser Val 35 40 45Cys Arg Ser Trp Ala Ala Trp Cys Lys Leu Asn Asn Arg Lys Trp Phe 50 55 60Pro Ala Glu Pro Glu Asp Val Arg Asp Tyr Leu Leu Tyr Leu Gln Ala 65 70 75 80Arg Gly Leu Ala Val Lys Thr Ile Gln Gln His Leu Gly Gln Leu Asn 85 90 95Met Leu His Arg Arg Ser Gly Leu Pro Arg Pro Ser Asp Ser Asn Ala 100 105 110Val Ser Leu Val Met Arg Arg Ile Arg Lys Glu Asn Val Asp Ala Gly 115 120 125Glu Arg Ala Lys Gln Ala Leu Ala Phe Glu Arg Thr Asp Phe Asp Gln 130 135 140Val Arg Ser Leu Met Glu Asn Ser Asp Arg Cys Gln Asp Ile Arg Asn145 150 155 160Leu Ala Phe Leu Gly Ile Ala Tyr Asn Thr Leu Leu Arg Ile Ala Glu 165 170 175Ile Ala Arg Ile Arg Val Lys Asp Ile Ser Arg Thr Asp Gly Gly Arg 180 185 190Met Leu Ile His Ile Gly Arg Thr Lys Thr Leu Val Ser Thr Ala Gly 195 200 205Val Glu Lys Ala Leu Ser Leu Gly Val Thr Lys Leu Val Glu Arg Trp 210 215 220Ile Ser Val Ser Gly Val Ala Asp Asp Pro Asn Asn Tyr Leu Phe Cys225 230 235 240Arg Val Arg Lys Asn Gly Val Ala Ala Pro Ser Ala Thr Ser Gln Leu 245 250 255Ser Thr Arg Ala Leu Glu Gly Ile Phe Glu Ala Thr His Arg Leu Ile 260 265 270Tyr Gly Ala Lys Asp Asp Ser Gly Gln Arg Tyr Leu Ala Trp Ser Gly 275 280 285His Ser Ala Arg Val Gly Ala Ala Arg Asp Met Ala Arg Ala Gly Val 290 295 300Ser Ile Pro Glu Ile Met Gln Ala Gly Gly Trp Thr Asn Val Asn Ile305 310 315 320Val Met Asn Tyr Ile Arg Asn Leu Asp Ser Glu Thr Gly Ala Met Val 325 330 335Arg Leu Leu Glu Asp Gly Asp Gly Gly Gly Ser Gly Gly Gly Ser Gly 340 345 350Gly Gly Ser Asp Pro Thr Met Pro Gln Phe Asp Ile Leu Cys Lys Thr 355 360 365Pro Pro Lys Val Leu Val Arg Gln Phe Val Glu Arg Phe Glu Arg Pro 370 375 380Ser Gly Glu Lys Ile Ala Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys385 390 395 400Trp Met Ile Thr His Asn Gly Thr Ala Ile Lys Arg Ala Thr Phe Met 405 410 415Ser Tyr Asn Thr Ile Ile Ser Asn Ser Leu Ser Phe Asp Ile Val Asn 420 425 430Lys Ser Leu Gln Phe Lys Tyr Lys Thr Gln Lys Ala Thr Ile Leu Glu 435 440 445Ala Ser Leu Lys Lys Leu Ile Pro Ala Trp Glu Phe Thr Ile Ile Pro 450 455 460Tyr Tyr Gly Gln Lys His Gln Ser Asp Ile Thr Asp Ile Val Ser Ser465 470 475 480Leu Gln Leu Gln Phe Glu Ser Ser Glu Glu Ala Asp Lys Gly Asn Ser 485 490 495His Ser Lys Lys Met Leu Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile 500 505 510Trp Glu Ile Thr Glu Lys Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg 515 520 525Phe Thr Lys Thr Lys Thr Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe 530 535 540Ile Asn Cys Gly Arg Phe Ser Asp Ile Lys Asn Val Asp Pro Lys Ser545 550 555 560Phe Lys Leu Val Gln Asn Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu 565 570 575Val Thr Glu Thr Lys Thr Ser Val Ser Arg His Ile Tyr Phe Phe Ser 580 585 590Ala Arg Gly Arg Ile Asp Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg 595 600 605Asn Ser Glu Pro Val Leu Lys Arg Val Asn Arg Thr Gly Asn Ser Ser 610 615 620Ser Asn Lys Gln Glu Tyr Gln Leu Leu Lys Asp Asn Leu Val Arg Ser625 630 635 640Tyr Asn Lys Ala Leu Lys Lys Asn Ala Pro Tyr Ser Ile Phe Ala Ile 645 650 655Lys Asn Gly Pro Lys Ser His Ile Gly Arg His Leu Met Thr Ser Phe 660 665 670Leu Ser Met Lys Gly Leu Thr Glu Leu Thr Asn Val Val Gly Asn Trp 675 680 685Ser Asp Lys Arg Ala Ser Ala Val Ala Arg Thr Thr Tyr Thr His Gln 690 695 700Ile Thr Ala Ile Pro Asp His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr705 710 715 720Ala Tyr Asp Pro Ile Ser Lys Glu Met Ile Ala Leu Lys Asp Glu Thr 725 730 735Asn Pro Ile Glu Glu Trp Gln His Ile Glu Gln Leu Lys Gly Ser Ala 740 745 750Glu Gly Ser Ile Arg Tyr Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu 755 760 765Val Leu Asp Tyr Leu Ser Ser Tyr Ile Asn Arg Arg Ile 770 775 780 4 2346 DNA Artificial Sequence Description of Artificial SequenceNucleotide sequence encoding a CreFLPm polypeptide, Cre from Bacteriophage P1 and FLP (Maize preferred codons) from Saccharomyces 4atggccaatt tactgaccgt acaccaaaat ttgcctgcat taccggtcga tgcaacgagt 60gatgaggttc gcaagaacct gatggacatg ttcagggatc gccaggcgtt ttctgagcat 120acctggaaaa tgcttctgtc cgtttgccgg tcgtgggcgg catggtgcaa gttgaataac 180cggaaatggt ttcccgcaga acctgaagat gttcgcgatt atcttctata tcttcaggcg 240cgcggtctgg cagtaaaaac tatccagcaa catttgggcc agctaaacat gcttcatcgt 300cggtccgggc tgccacgacc aagtgacagc aatgctgttt cactggttat gcggcggatc 360cgaaaagaaa acgttgatgc cggtgaacgt gcaaaacagg ctctagcgtt cgaacgcact 420gatttcgacc aggttcgttc actcatggaa aatagcgatc gctgccagga tatacgtaat 480ctggcatttc tggggattgc ttataacacc ctgttacgta tagccgaaat tgccaggatc 540agggttaaag atatctcacg tactgacggt gggagaatgt taatccatat tggcagaacg 600aaaacgctgg ttagcaccgc aggtgtagag aaggcactta gcctgggggt aactaaactg 660gtcgagcgat ggatttccgt ctctggtgta gctgatgatc cgaataacta cctgttttgc 720cgggtcagaa aaaatggtgt tgccgcgcca tctgccacca gccagctatc aactcgcgcc 780ctggaaggga tttttgaagc aactcatcga ttgatttacg gcgctaagga tgactctggt 840cagagatacc tggcctggtc tggacacagt gcccgtgtcg gagccgcgcg agatatggcc 900cgcgctggag tttcaatacc ggagatcatg caagctggtg gctggaccaa tgtaaatatt 960gtcatgaact atatccgtaa cctggatagt gaaacagggg caatggtgcg cctgctggaa 1020gatggcgatg gtggcggcag cggtggcggc tccggcggtg gctcggatcc aacaatgccc 1080cagttcgaca tcctctgcaa gacccccccc aaggtgctcg tgaggcagtt cgtggagagg 1140ttcgagaggc cctccggcga gaagatcgcc ctctgcgccg ccgagctcac ctacctctgc 1200tggatgatca cccacaacgg caccgccatt aagagggcca ccttcatgtc atacaacacc 1260atcatctcca actccctctc cttcgacatc gtgaacaagt ccctccagtt caaatacaag 1320acccagaagg ccaccatcct cgaggcctcc ctcaagaagc tcatccccgc ctgggagttc 1380accatcatcc cctactacgg ccagaagcac cagtccgaca tcaccgacat cgtgtcatcc 1440ctccagcttc agttcgagtc ctccgaggag gctgacaagg gcaactccca ctccaagaag 1500atgctgaagg ccctcctctc cgagggcgag tccatctggg agatcaccga gaagatcctc 1560aactccttcg agtacacctc caggttcact aagaccaaga ccctctacca gttcctcttc 1620ctcgccacct tcatcaactg cggcaggttc tcagacatca agaacgtgga ccccaagtcc 1680ttcaagctcg tgcagaacaa gtacctcggc gtgatcatcc agtgcctcgt gaccgagacc 1740aagacctccg tgtccaggca catctacttc ttctccgctc gcggcaggat cgaccccctc 1800gtgtacctcg acgagttcct caggaactca gagcccgtgc tcaagagggt gaacaggacc 1860ggcaactcct cctccaacaa gcaggagtac cagctcctca aggacaacct cgtgaggtcc 1920tacaacaagg ccctcaagaa gaacgccccc tactccatct tcgccatcaa gaacggcccc 1980aagtcccaca tcggtaggca cctcatgacc tccttcctct caatgaaggg cctcaccgag 2040ctcaccaacg tggtgggcaa ctggtccgac aagagggcct ccgccgtggc caggaccacc 2100tacacccacc agatcaccgc catccccgac cactacttcg ccctcgtgtc aaggtactac 2160gcctacgacc ccatctccaa ggagatgatc gccctcaagg acgagactaa ccccatcgag 2220gagtggcagc acatcgagca gctcaagggc tccgccgagg gctccatcag gtaccccgcc 2280tggaacggca tcatctccca ggaggtgctc gactacctct cctcctacat caacaggagg 2340atctga 2346 5 2346 DNA Artificial Sequence Description of Artificial Sequence sequence encoding moCreFLPm, Cre from Bacteriophage P1 and FLP from Saccharomyces, both maize preferred codons 5atg tcc aac ctg ctc acg gtt cac cag aac ctt ccg gct ctt cca gtg 48Met Ser Asn Leu Leu Thr Val His Gln Asn Leu Pro Ala Leu Pro Val 1 5 10 15gac gcg acg tcc gat gaa gtc agg aag aac ctc atg gac atg ttc cgc 96Asp Ala Thr Ser Asp Glu Val Arg Lys Asn Leu Met Asp Met Phe Arg 20 25 30gac agg caa gcg ttc agc gag cac acc tgg aag atg ctg ctc tcc gtc 144Asp Arg Gln Ala Phe Ser Glu His Thr Trp Lys Met Leu Leu Ser Val 35 40 45tgc cgc tcc tgg gct gca tgg tgc aag ctg aac aac agg aag tgg ttc 192Cys Arg Ser Trp Ala Ala Trp Cys Lys Leu Asn Asn Arg Lys Trp Phe 50 55 60ccc gct gag ccc gag gac gtg agg gat tac ctt ctg tac ctg caa gct 240Pro Ala Glu Pro Glu Asp Val Arg Asp Tyr Leu Leu Tyr Leu Gln Ala 65 70 75 80cgc ggg ctg gca gtg aag acc atc cag caa cac ctt gga caa ctg aac 288Arg Gly Leu Ala Val Lys Thr Ile Gln Gln His Leu Gly Gln Leu Asn 85 90 95atg ctt cac agg cgc tcc ggc ctc ccg cgc ccc agc gac tcg aac gcc 336Met Leu His Arg Arg Ser Gly Leu Pro Arg Pro Ser Asp Ser Asn Ala 100 105 110gtg agc ctc gtc atg cgc cgc atc agg aag gaa aac gtc gat gcc ggc 384Val Ser Leu Val Met Arg Arg Ile Arg Lys Glu Asn Val Asp Ala Gly 115 120 125gaa agg gca aag cag gcc ctc gcg ttc gag agg acc gat ttc gac cag 432Glu Arg Ala Lys Gln Ala Leu Ala Phe Glu Arg Thr Asp Phe Asp Gln 130 135 140gtc cgc agc ctg atg gag aac agc gac agg tgc cag gac att agg aac 480Val Arg Ser Leu Met Glu Asn Ser Asp Arg Cys Gln Asp Ile Arg Asn145 150 155 160ctg gcg ttc ctc gga att gca tac aac acg ctc ctc agg atc gcg gaa 528Leu Ala Phe Leu Gly Ile Ala Tyr Asn Thr Leu Leu Arg Ile Ala Glu 165 170 175att gcc cgc att cgc gtg aag gac att agc cgc acc gac ggc ggc agg 576Ile Ala Arg Ile Arg Val Lys Asp Ile Ser Arg Thr Asp Gly Gly Arg 180 185 190atg ctt atc cac att ggc agg acc aag acg ctc gtt tcc acc gca ggc 624Met Leu Ile His Ile Gly Arg Thr Lys Thr Leu Val Ser Thr Ala Gly 195 200 205gtc gaa aag gcc ctc agc ctc gga gtg acc aag ctc gtc gaa cgc tgg 672Val Glu Lys Ala Leu Ser Leu Gly Val Thr Lys Leu Val Glu Arg Trp 210 215 220atc tcc gtg tcc ggc gtc gcg gac gac cca aac aac tac ctc ttc tgc 720Ile Ser Val Ser Gly Val Ala Asp Asp Pro Asn Asn Tyr Leu Phe Cys225 230 235 240cgc gtc cgc aag aac ggg gtg gct gcc cct agc gcc acc agc caa ctc 768Arg Val Arg Lys Asn Gly Val Ala Ala Pro Ser Ala Thr Ser Gln Leu 245 250 255agc acg agg gcc ttg gaa ggt att ttc gag gcc acc cac cgc ctg atc 816Ser Thr Arg Ala Leu Glu Gly Ile Phe Glu Ala Thr His Arg Leu Ile 260 265 270tac ggc gcg aag gat gac agc ggt caa cgc tac ctc gca tgg tcc ggg 864Tyr Gly Ala Lys Asp Asp Ser Gly Gln Arg Tyr Leu Ala Trp Ser Gly 275 280 285cac tcc gcc cgc gtt gga gct gct agg gac atg gcc cgc gcc ggt gtt 912His Ser Ala Arg Val Gly Ala Ala Arg Asp Met Ala Arg Ala Gly Val 290 295 300tcc atc ccc gaa atc atg cag gcg ggt gga tgg acg aac gtg aac att 960Ser Ile Pro Glu Ile Met Gln Ala Gly Gly Trp Thr Asn Val Asn Ile305 310 315 320gtc atg aac tac att cgc aac ctt gac agc gag acg ggc gca atg gtt 1008Val Met Asn Tyr Ile Arg Asn Leu Asp Ser Glu Thr Gly Ala Met Val 325 330 335cgc ctc ctg gaa gat ggc gat ggt ggc ggc agc ggt ggc ggc tcc ggc 1056Arg Leu Leu Glu Asp Gly Asp Gly Gly Gly Ser Gly Gly Gly Ser Gly 340 345 350ggt ggc tcg gat cca aca atg ccc cag ttc gac atc ctc tgc aag acc 1104Gly Gly Ser Asp Pro Thr Met Pro Gln Phe Asp Ile Leu Cys Lys Thr 355 360 365ccc ccc aag gtg ctc gtg agg cag ttc gtg gag agg ttc gag agg ccc 1152Pro Pro Lys Val Leu Val Arg Gln Phe Val Glu Arg Phe Glu Arg Pro 370 375 380tcc ggc gag aag atc gcc ctc tgc gcc gcc gag ctc acc tac ctc tgc 1200Ser Gly Glu Lys Ile Ala Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys385 390 395 400tgg atg atc acc cac aac ggc acc gcc att aag agg gcc acc ttc atg 1248Trp Met Ile Thr His Asn Gly Thr Ala Ile Lys Arg Ala Thr Phe Met 405 410 415tca tac aac acc atc atc tcc aac tcc ctc tcc ttc gac atc gtg aac 1296Ser Tyr Asn Thr Ile Ile Ser Asn Ser Leu Ser Phe Asp Ile Val Asn 420 425 430aag tcc ctc cag ttc aaa tac aag acc cag aag gcc acc atc ctc gag 1344Lys Ser Leu Gln Phe Lys Tyr Lys Thr Gln Lys Ala Thr Ile Leu Glu 435 440 445gcc tcc ctc aag aag ctc atc ccc gcc tgg gag ttc acc atc atc ccc 1392Ala Ser Leu Lys Lys Leu Ile Pro Ala Trp Glu Phe Thr Ile Ile Pro 450 455 460tac tac ggc cag aag cac cag tcc gac atc acc gac atc gtg tca tcc 1440Tyr Tyr Gly Gln Lys His Gln Ser Asp Ile Thr Asp Ile Val Ser Ser465 470 475 480ctc cag ctt cag ttc gag tcc tcc gag gag gct gac aag ggc aac tcc 1488Leu Gln Leu Gln Phe Glu Ser Ser Glu Glu Ala Asp Lys Gly Asn Ser 485 490 495cac tcc aag aag atg ctg aag gcc ctc ctc tcc gag ggc gag tcc atc 1536His Ser Lys Lys Met Leu Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile 500 505 510tgg gag atc acc gag aag atc ctc aac tcc ttc gag tac acc tcc agg 1584Trp Glu Ile Thr Glu Lys Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg 515 520 525ttc act aag acc aag acc ctc tac cag ttc ctc ttc ctc gcc acc ttc 1632Phe Thr Lys Thr Lys Thr Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe 530 535 540atc aac tgc ggc agg ttc tca gac atc aag aac gtg gac ccc aag tcc 1680Ile Asn Cys Gly Arg Phe Ser Asp Ile Lys Asn Val Asp Pro Lys Ser545 550 555 560ttc aag ctc gtg cag aac aag tac ctc ggc gtg atc atc cag tgc ctc 1728Phe Lys Leu Val Gln Asn Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu 565 570 575gtg acc gag acc aag acc tcc gtg tcc agg cac atc tac ttc ttc tcc 1776Val Thr Glu Thr Lys Thr Ser Val Ser Arg His Ile Tyr Phe Phe Ser 580 585 590gct cgc ggc agg atc gac ccc ctc gtg tac ctc gac gag ttc ctc agg 1824Ala Arg Gly Arg Ile Asp Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg 595 600 605aac tca gag ccc gtg ctc aag agg gtg aac agg acc ggc aac tcc tcc 1872Asn Ser Glu Pro Val Leu Lys Arg Val Asn Arg Thr Gly Asn Ser Ser 610 615 620tcc aac aag cag gag tac cag ctc ctc aag gac aac ctc gtg agg tcc 1920Ser Asn Lys Gln Glu Tyr Gln Leu Leu Lys Asp Asn Leu Val Arg Ser625 630 635 640tac aac aag gcc ctc aag aag aac gcc ccc tac tcc atc ttc gcc atc 1968Tyr Asn Lys Ala Leu Lys Lys Asn Ala Pro Tyr Ser Ile Phe Ala Ile 645 650 655aag aac ggc ccc aag tcc cac atc ggt agg cac ctc atg acc tcc ttc 2016Lys Asn Gly Pro Lys Ser His Ile Gly Arg His Leu Met Thr Ser Phe 660 665 670ctc tca atg aag ggc ctc acc gag ctc acc aac gtg gtg ggc aac tgg 2064Leu Ser Met Lys Gly Leu Thr Glu Leu Thr Asn Val Val Gly Asn Trp 675 680 685tcc gac aag agg gcc tcc gcc gtg gcc agg acc acc tac acc cac cag 2112Ser Asp Lys Arg Ala Ser Ala Val Ala Arg Thr Thr Tyr Thr His Gln 690 695 700atc acc gcc atc ccc gac cac tac ttc gcc ctc gtg tca agg tac tac 2160Ile Thr Ala Ile Pro Asp His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr705 710 715 720gcc tac gac ccc atc tcc aag gag atg atc gcc ctc aag gac gag act 2208Ala Tyr Asp Pro Ile Ser Lys Glu Met Ile Ala Leu Lys Asp Glu Thr 725 730 735aac ccc atc gag gag tgg cag cac atc gag cag ctc aag ggc tcc gcc 2256Asn Pro Ile Glu Glu Trp Gln His Ile Glu Gln Leu Lys Gly Ser Ala 740 745 750gag ggc tcc atc agg tac ccc gcc tgg aac ggc atc atc tcc cag gag 2304Glu Gly Ser Ile Arg Tyr Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu 755 760 765gtg ctc gac tac ctc tcc tcc tac atc aac agg agg atc tga 2346Val Leu Asp Tyr Leu Ser Ser Tyr Ile Asn Arg Arg Ile 770 775 780 6 781 PRT Artificial Sequence Description of Artificial Sequence sequence 6Met Ser Asn Leu Leu Thr Val His Gln Asn Leu Pro Ala Leu Pro Val 1 5 10 15Asp Ala Thr Ser Asp Glu Val Arg Lys Asn Leu Met Asp Met Phe Arg 20 25 30Asp Arg Gln Ala Phe Ser Glu His Thr Trp Lys Met Leu Leu Ser Val 35 40 45Cys Arg Ser Trp Ala Ala Trp Cys Lys Leu Asn Asn Arg Lys Trp Phe 50 55 60Pro Ala Glu Pro Glu Asp Val Arg Asp Tyr Leu Leu Tyr Leu Gln Ala 65 70 75 80Arg Gly Leu Ala Val Lys Thr Ile Gln Gln His Leu Gly Gln Leu Asn 85 90 95Met Leu His Arg Arg Ser Gly Leu Pro Arg Pro Ser Asp Ser Asn Ala 100 105 110Val Ser Leu Val Met Arg Arg Ile Arg Lys Glu Asn Val Asp Ala Gly 115 120 125Glu Arg Ala Lys Gln Ala Leu Ala Phe Glu Arg Thr Asp Phe Asp Gln 130 135 140Val Arg Ser Leu Met Glu Asn Ser Asp Arg Cys Gln Asp Ile Arg Asn145 150 155 160Leu Ala Phe Leu Gly Ile Ala Tyr Asn Thr Leu Leu Arg Ile Ala Glu 165 170 175Ile Ala Arg Ile Arg Val Lys Asp Ile Ser Arg Thr Asp Gly Gly Arg 180 185 190Met Leu Ile His Ile Gly Arg Thr Lys Thr Leu Val Ser Thr Ala Gly 195 200 205Val Glu Lys Ala Leu Ser Leu Gly Val Thr Lys Leu Val Glu Arg Trp 210 215 220Ile Ser Val Ser Gly Val Ala Asp Asp Pro Asn Asn Tyr Leu Phe Cys225 230 235 240Arg Val Arg Lys Asn Gly Val Ala Ala Pro Ser Ala Thr Ser Gln Leu 245 250 255Ser Thr Arg Ala Leu Glu Gly Ile Phe Glu Ala Thr His Arg Leu Ile 260 265 270Tyr Gly Ala Lys Asp Asp Ser Gly Gln Arg Tyr Leu Ala Trp Ser Gly 275 280 285His Ser Ala Arg Val Gly Ala Ala Arg Asp Met Ala Arg Ala Gly Val 290 295 300Ser Ile Pro Glu Ile Met Gln Ala Gly Gly Trp Thr Asn Val Asn Ile305 310 315 320Val Met Asn Tyr Ile Arg Asn Leu Asp Ser Glu Thr Gly Ala Met Val 325 330 335Arg Leu Leu Glu Asp Gly Asp Gly Gly Gly Ser Gly Gly Gly Ser Gly 340 345 350Gly Gly Ser Asp Pro Thr Met Pro Gln Phe Asp Ile Leu Cys Lys Thr 355 360 365Pro Pro Lys Val Leu Val Arg Gln Phe Val Glu Arg Phe Glu Arg Pro 370 375 380Ser Gly Glu Lys Ile Ala Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys385 390 395 400Trp Met Ile Thr His Asn Gly Thr Ala Ile Lys Arg Ala Thr Phe Met 405 410 415Ser Tyr Asn Thr Ile Ile Ser Asn Ser Leu Ser Phe Asp Ile Val Asn 420 425 430Lys Ser Leu Gln Phe Lys Tyr Lys Thr Gln Lys Ala Thr Ile Leu Glu 435 440 445Ala Ser Leu Lys Lys Leu Ile Pro Ala Trp Glu Phe Thr Ile Ile Pro 450 455 460Tyr Tyr Gly Gln Lys His Gln Ser Asp Ile Thr Asp Ile Val Ser Ser465 470 475 480Leu Gln Leu Gln Phe Glu Ser Ser Glu Glu Ala Asp Lys Gly Asn Ser 485 490 495His Ser Lys Lys Met Leu Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile 500 505 510Trp Glu Ile Thr Glu Lys Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg 515 520 525Phe Thr Lys Thr Lys Thr Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe 530 535 540Ile Asn Cys Gly Arg Phe Ser Asp Ile Lys Asn Val Asp Pro Lys Ser545 550 555 560Phe Lys Leu Val Gln Asn Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu 565 570 575Val Thr Glu Thr Lys Thr Ser Val Ser Arg His Ile Tyr Phe Phe Ser 580 585 590Ala Arg Gly Arg Ile Asp Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg 595 600 605Asn Ser Glu Pro Val Leu Lys Arg Val Asn Arg Thr Gly Asn Ser Ser 610 615 620Ser Asn Lys Gln Glu Tyr Gln Leu Leu Lys Asp Asn Leu Val Arg Ser625 630 635 640Tyr Asn Lys Ala Leu Lys Lys Asn Ala Pro Tyr Ser Ile Phe Ala Ile 645 650 655Lys Asn Gly Pro Lys Ser His Ile Gly Arg His Leu Met Thr Ser Phe 660 665 670Leu Ser Met Lys Gly Leu Thr Glu Leu Thr Asn Val Val Gly Asn Trp 675 680 685Ser Asp Lys Arg Ala Ser Ala Val Ala Arg Thr Thr Tyr Thr His Gln 690 695 700Ile Thr Ala Ile Pro Asp His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr705 710 715 720Ala Tyr Asp Pro Ile Ser Lys Glu Met Ile Ala Leu Lys Asp Glu Thr 725 730 735Asn Pro Ile Glu Glu Trp Gln His Ile Glu Gln Leu Lys Gly Ser Ala 740 745 750Glu Gly Ser Ile Arg Tyr Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu 755 760 765Val Leu Asp Tyr Leu Ser Ser Tyr Ile Asn Arg Arg Ile 770 775 780 7 2346 DNA Artificial Sequence Description of Artificial Sequence sequence encoding a CreFLP polypeptide , Cre from Bacteriophage P1 and FLP from Saccharomyces 7atggccaatt tactgaccgt acaccaaaat ttgcctgcat taccggtcga tgcaacgagt 60gatgaggttc gcaagaacct gatggacatg ttcagggatc gccaggcgtt ttctgagcat 120acctggaaaa tgcttctgtc cgtttgccgg tcgtgggcgg catggtgcaa gttgaataac 180cggaaatggt ttcccgcaga acctgaagat gttcgcgatt atcttctata tcttcaggcg 240cgcggtctgg cagtaaaaac tatccagcaa catttgggcc agctaaacat gcttcatcgt 300cggtccgggc tgccacgacc aagtgacagc aatgctgttt cactggttat gcggcggatc 360cgaaaagaaa acgttgatgc cggtgaacgt gcaaaacagg ctctagcgtt cgaacgcact 420gatttcgacc aggttcgttc actcatggaa aatagcgatc gctgccagga tatacgtaat 480ctggcatttc tggggattgc ttataacacc ctgttacgta tagccgaaat tgccaggatc 540agggttaaag atatctcacg tactgacggt gggagaatgt taatccatat tggcagaacg 600aaaacgctgg ttagcaccgc aggtgtagag aaggcactta gcctgggggt aactaaactg 660gtcgagcgat ggatttccgt ctctggtgta gctgatgatc cgaataacta cctgttttgc 720cgggtcagaa aaaatggtgt tgccgcgcca tctgccacca gccagctatc aactcgcgcc 780ctggaaggga tttttgaagc aactcatcga ttgatttacg gcgctaagga tgactctggt 840cagagatacc tggcctggtc tggacacagt gcccgtgtcg gagccgcgcg agatatggcc 900cgcgctggag tttcaatacc ggagatcatg caagctggtg gctggaccaa tgtaaatatt 960gtcatgaact atatccgtaa cctggatagt gaaacagggg caatggtgcg cctgctggaa 1020gatggcgatg gtggcggcag cggtggcggc tccggcggtg gctcggatcc aacaatgcca 1080caatttgata tattatgtaa aacaccacct aaggtgcttg ttcgtcagtt tgtggaaagg 1140tttgagagac cttccggaga gaaaatagca ttatgtgctg ctgaactaac ctatttatgt 1200tggatgatta cacataacgg aacagcaatc aagagagcca cattcatgag ctataatact 1260atcataagca attcgctgag tttggatatc gtcaacaagt cactgcagtt taaatacaag 1320acgcaaaaag caacaattct ggaagcctca ttaaagaaat tgattcctgc ttgggaattt 1380acaattattc cttactatgg acaaaaacat caatctgata tcactgatat tgtaagtagt 1440ttgcaattac agttcgaatc atcggaagaa gcagataagg gaaatagcca cagtaaaaaa 1500atgcttaaag cacttctaag tgagggtgaa agcatctggg agatcactga gaaaatacta 1560aattcgtttg agtatacttc gagatttaca aaaacaaaaa ctttatacca attcctcttc 1620ctagctactt tcatcaattg tggaagattc agcgatatta agaacgttga tccgaaatca 1680tttaaattag tccaaaataa gtatctggga gtaataatcc agtgtttagt gacagagaca 1740aagacaagcg ttagtaggca catatacttc tttagcgcaa ggggtaggat cgatccactt 1800gtatatttgg atgaattttt gaggaattct gaaccagtcc taaaacgagt aaataggacc 1860ggcaattctt caagcaacaa gcaggaatac caattattaa aagataactt agtcagatcg 1920tacaacaaag ctttgaagaa aaatgcgcct tattcaatct ttgctataaa aaatggccca 1980aaatctcaca ttggaagaca tttgatgacc tcatttcttt caatgaaggg cctaacggag 2040ttgactaatg ttgtgggaaa ttggagcgat aagcgtgctt ctgccgtggc caggacaacg 2100tatactcatc agataacagc aatacctgat cactacttcg cactagtttc tcggtactat 2160gcatatgatc caatatcaaa ggaaatgata gcattgaagg atgagactaa tccaattgag 2220gagtggcagc atatagaaca gctaaagggt agtgctgaag gaagcatacg ataccccgca 2280tggaatggga taatatcaca ggaggtacta gactaccttt catcctacat aaatagacgc 2340atataa 2346 8 2346 DNA Artificial Sequence Description of Artificial Sequence Sequence encoding a FLPmCre polypeptide, FLP from Saccharomyces (maize preferred codons), and Cre from Bacteriophage P1 8atg ccc cag ttc gac atc ctc tgc aag acc ccc ccc aag gtg ctc gtg 48Met Pro Gln Phe Asp Ile Leu Cys Lys Thr Pro Pro Lys Val Leu Val 1 5 10 15agg cag ttc gtg gag agg ttc gag agg ccc tcc ggc gag aag atc gcc 96Arg Gln Phe Val Glu Arg Phe Glu Arg Pro Ser Gly Glu Lys Ile Ala 20 25 30ctc tgc gcc gcc gag ctc acc tac ctc tgc tgg atg atc acc cac aac 144Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys Trp Met Ile Thr His Asn 35 40 45ggc acc gcc att aag agg gcc acc ttc atg tca tac aac acc atc atc 192Gly Thr Ala Ile Lys Arg Ala Thr Phe Met Ser Tyr Asn Thr Ile Ile 50 55 60tcc aac tcc ctc tcc ttc gac atc gtg aac aag tcc ctc cag ttc aaa 240Ser Asn Ser Leu Ser Phe Asp Ile Val Asn Lys Ser Leu Gln Phe Lys 65 70 75 80tac aag acc cag aag gcc acc atc ctc gag gcc tcc ctc aag aag ctc 288Tyr Lys Thr Gln Lys Ala Thr Ile Leu Glu Ala Ser Leu Lys Lys Leu 85 90 95atc ccc gcc tgg gag ttc acc atc atc ccc tac tac ggc cag aag cac 336Ile Pro Ala Trp Glu Phe Thr Ile Ile Pro Tyr Tyr Gly Gln Lys His 100 105 110cag tcc gac atc acc gac atc gtg tca tcc ctc cag ctt cag ttc gag 384Gln Ser Asp Ile Thr Asp Ile Val Ser Ser Leu Gln Leu Gln Phe Glu 115 120 125tcc tcc gag gag gct gac aag ggc aac tcc cac tcc aag aag atg ctg 432Ser Ser Glu Glu Ala Asp Lys Gly Asn Ser His Ser Lys Lys Met Leu 130 135 140aag gcc ctc ctc tcc gag ggc gag tcc atc tgg gag atc acc gag aag 480Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile Trp Glu Ile Thr Glu Lys145 150 155 160atc ctc aac tcc ttc gag tac acc tcc agg ttc act aag acc aag acc 528Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg Phe Thr Lys Thr Lys Thr 165 170 175ctc tac cag ttc ctc ttc ctc gcc acc ttc atc aac tgc ggc agg ttc 576Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe Ile Asn Cys Gly Arg Phe 180 185 190tca gac atc aag aac gtg gac ccc aag tcc ttc aag ctc gtg cag aac 624Ser Asp Ile Lys Asn Val Asp Pro Lys Ser Phe Lys Leu Val Gln Asn 195 200 205aag tac ctc ggc gtg atc atc cag tgc ctc gtg acc gag acc aag acc 672Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu Val Thr Glu Thr Lys Thr 210 215 220tcc gtg tcc agg cac atc tac ttc ttc tcc gct cgc ggc agg atc gac 720Ser Val Ser Arg His Ile Tyr Phe Phe Ser Ala Arg Gly Arg Ile Asp225 230 235 240ccc ctc gtg tac ctc gac gag ttc ctc agg aac tca gag ccc gtg ctc 768Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg Asn Ser Glu Pro Val Leu 245 250 255aag agg gtg aac agg acc ggc aac tcc tcc tcc aac aag cag gag tac 816Lys Arg Val Asn Arg Thr Gly Asn Ser Ser Ser Asn Lys Gln Glu Tyr 260 265 270cag ctc ctc aag gac aac ctc gtg agg tcc tac aac aag gcc ctc aag 864Gln Leu Leu Lys Asp Asn Leu Val Arg Ser Tyr Asn Lys Ala Leu Lys 275 280 285aag aac gcc ccc tac tcc atc ttc gcc atc aag aac ggc ccc aag tcc 912Lys Asn Ala Pro Tyr Ser Ile Phe Ala Ile Lys Asn Gly Pro Lys Ser 290 295 300cac atc ggt agg cac ctc atg acc tcc ttc ctc tca atg aag ggc ctc 960His Ile Gly Arg His Leu Met Thr Ser Phe Leu Ser Met Lys Gly Leu305 310 315 320acc gag ctc acc aac gtg gtg ggc aac tgg tcc gac aag agg gcc tcc 1008Thr Glu Leu Thr Asn Val Val Gly Asn Trp Ser Asp Lys Arg Ala Ser 325 330 335gcc gtg gcc agg acc acc tac acc cac cag atc acc gcc atc ccc gac 1056Ala Val Ala Arg Thr Thr Tyr Thr His Gln Ile Thr Ala Ile Pro Asp 340 345 350cac tac ttc gcc ctc gtg tca agg tac tac gcc tac gac ccc atc tcc 1104His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr Ala Tyr Asp Pro Ile Ser 355 360 365aag gag atg atc gcc ctc aag gac gag act aac ccc atc gag gag tgg 1152Lys Glu Met Ile Ala Leu Lys Asp Glu Thr Asn Pro Ile Glu Glu Trp 370 375 380cag cac atc gag cag ctc aag ggc tcc gcc gag ggc tcc atc agg tac 1200Gln His Ile Glu Gln Leu Lys Gly Ser Ala Glu Gly Ser Ile Arg Tyr385 390 395 400ccc gcc tgg aac ggc atc atc tcc cag gag gtg ctc gac tac ctc tcc 1248Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu Val Leu Asp Tyr Leu Ser 405 410 415tcc tac atc aac agg agg atc ggt ggc ggc agc ggt ggc ggc tcc ggc 1296Ser Tyr Ile Asn Arg Arg Ile Gly Gly Gly Ser Gly Gly Gly Ser Gly 420 425 430ggt ggc tcg gat cca acc atg gcc aat tta ctg acc gta cac caa aat 1344Gly Gly Ser Asp Pro Thr Met Ala Asn Leu Leu Thr Val His Gln Asn 435 440 445ttg cct gca tta ccg gtc gat gca acg agt gat gag gtt cgc aag aac 1392Leu Pro Ala Leu Pro Val Asp Ala Thr Ser Asp Glu Val Arg Lys Asn 450 455 460ctg atg gac atg ttc agg gat cgc cag gcg ttt tct gag cat acc tgg 1440Leu Met Asp Met Phe Arg Asp Arg Gln Ala Phe Ser Glu His Thr Trp465 470 475 480aaa atg ctt ctg tcc gtt tgc cgg tcg tgg gcg gca tgg tgc aag ttg 1488Lys Met Leu Leu Ser Val Cys Arg Ser Trp Ala Ala Trp Cys Lys Leu 485 490 495aat aac cgg aaa tgg ttt ccc gca gaa cct gaa gat gtt cgc gat tat 1536Asn Asn Arg Lys Trp Phe Pro Ala Glu Pro Glu Asp Val Arg Asp Tyr 500 505 510ctt cta tat ctt cag gcg cgc ggt ctg gca gta aaa act atc cag caa 1584Leu Leu Tyr Leu Gln Ala Arg Gly Leu Ala Val Lys Thr Ile Gln Gln 515 520 525cat ttg ggc cag cta aac atg ctt cat cgt cgg tcc ggg ctg cca cga 1632His Leu Gly Gln Leu Asn Met Leu His Arg Arg Ser Gly Leu Pro Arg 530 535 540cca agt gac agc aat gct gtt tca ctg gtt atg cgg cgg atc cga aaa 1680Pro Ser Asp Ser Asn Ala Val Ser Leu Val Met Arg Arg Ile Arg Lys545 550 555 560gaa aac gtt gat gcc ggt gaa cgt gca aaa cag gct cta gcg ttc gaa 1728Glu Asn Val Asp Ala Gly Glu Arg Ala Lys Gln Ala Leu Ala Phe Glu 565 570 575cgc act gat ttc gac cag gtt cgt tca ctc atg gaa aat agc gat cgc 1776Arg Thr Asp Phe Asp Gln Val Arg Ser Leu Met Glu Asn Ser Asp Arg 580 585 590tgc cag gat ata cgt aat ctg gca ttt ctg ggg att gct tat aac acc 1824Cys Gln Asp Ile Arg Asn Leu Ala Phe Leu Gly Ile Ala Tyr Asn Thr 595 600 605ctg tta cgt ata gcc gaa att gcc agg atc agg gtt aaa gat atc tca 1872Leu Leu Arg Ile Ala Glu Ile Ala Arg Ile Arg Val Lys Asp Ile Ser 610 615 620cgt act gac ggt ggg aga atg tta atc cat att ggc aga acg aaa acg 1920Arg Thr Asp Gly Gly Arg Met Leu Ile His Ile Gly Arg Thr Lys Thr625 630 635 640ctg gtt agc acc gca ggt gta gag aag gca ctt agc ctg ggg gta act 1968Leu Val Ser Thr Ala Gly Val Glu Lys Ala Leu Ser Leu Gly Val Thr 645 650 655aaa ctg gtc gag cga tgg att tcc gtc tct ggt gta gct gat gat ccg 2016Lys Leu Val Glu Arg Trp Ile Ser Val Ser Gly Val Ala Asp Asp Pro 660 665 670aat aac tac ctg ttt tgc cgg gtc aga aaa aat ggt gtt gcc gcg cca 2064Asn Asn Tyr Leu Phe Cys Arg Val Arg Lys Asn Gly Val Ala Ala Pro 675 680 685tct gcc acc agc cag cta tca act cgc gcc ctg gaa ggg att ttt gaa 2112Ser Ala Thr Ser Gln Leu Ser Thr Arg Ala Leu Glu Gly Ile Phe Glu 690 695 700gca act cat cga ttg att tac ggc gct aag gat gac tct ggt cag aga 2160Ala Thr His Arg Leu Ile Tyr Gly Ala Lys Asp Asp Ser Gly Gln Arg705 710 715 720tac ctg gcc tgg tct gga cac agt gcc cgt gtc gga gcc gcg cga gat 2208Tyr Leu Ala Trp Ser Gly His Ser Ala Arg Val Gly Ala Ala Arg Asp 725 730 735atg gcc cgc gct gga gtt tca ata ccg gag atc atg caa gct ggt ggc 2256Met Ala Arg Ala Gly Val Ser Ile Pro Glu Ile Met Gln Ala Gly Gly 740 745 750tgg acc aat gta aat att gtc atg aac tat atc cgt aac ctg gat agt 2304Trp Thr Asn Val Asn Ile Val Met Asn Tyr Ile Arg Asn Leu Asp Ser 755 760 765gaa aca ggg gca atg gtg cgc ctg ctg gaa gat ggc gat tag 2346Glu Thr Gly Ala Met Val Arg Leu Leu Glu Asp Gly Asp 770 775 780 9 781 PRT Artificial Sequence Description of Artificial Sequence Sequence 9Met Pro Gln Phe Asp Ile Leu Cys Lys Thr Pro Pro Lys Val Leu Val 1 5 10 15Arg Gln Phe Val Glu Arg Phe Glu Arg Pro Ser Gly Glu Lys Ile Ala 20 25 30Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys Trp Met Ile Thr His Asn 35 40 45Gly Thr Ala Ile Lys Arg Ala Thr Phe Met Ser Tyr Asn Thr Ile Ile 50 55 60Ser Asn Ser Leu Ser Phe Asp Ile Val Asn Lys Ser Leu Gln Phe Lys 65 70 75 80Tyr Lys Thr Gln Lys Ala Thr Ile Leu Glu Ala Ser Leu Lys Lys Leu 85 90 95Ile Pro Ala Trp Glu Phe Thr Ile Ile Pro Tyr Tyr Gly Gln Lys His 100 105 110Gln Ser Asp Ile Thr Asp Ile Val Ser Ser Leu Gln Leu Gln Phe Glu 115 120 125Ser Ser Glu Glu Ala Asp Lys Gly Asn Ser His Ser Lys Lys Met Leu 130 135 140Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile Trp Glu Ile Thr Glu Lys145 150 155 160Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg Phe Thr Lys Thr Lys Thr 165 170 175Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe Ile Asn Cys Gly Arg Phe 180 185 190Ser Asp Ile Lys Asn Val Asp Pro Lys Ser Phe Lys Leu Val Gln Asn 195 200 205Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu Val Thr Glu Thr Lys Thr 210 215 220Ser Val Ser Arg His Ile Tyr Phe Phe Ser Ala Arg Gly Arg Ile Asp225 230 235 240Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg Asn Ser Glu Pro Val Leu 245 250 255Lys Arg Val Asn Arg Thr Gly Asn Ser Ser Ser Asn Lys Gln Glu Tyr 260 265 270Gln Leu Leu Lys Asp Asn Leu Val Arg Ser Tyr Asn Lys Ala Leu Lys 275 280 285Lys Asn Ala Pro Tyr Ser Ile Phe Ala Ile Lys Asn Gly Pro Lys Ser 290 295 300His Ile Gly Arg His Leu Met Thr Ser Phe Leu Ser Met Lys Gly Leu305 310 315 320Thr Glu Leu Thr Asn Val Val Gly Asn Trp Ser Asp Lys Arg Ala Ser 325 330 335Ala Val Ala Arg Thr Thr Tyr Thr His Gln Ile Thr Ala Ile Pro Asp 340 345 350His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr Ala Tyr Asp Pro Ile Ser 355 360 365Lys Glu Met Ile Ala Leu Lys Asp Glu Thr Asn Pro Ile Glu Glu Trp 370 375 380Gln His Ile Glu Gln Leu Lys Gly Ser Ala Glu Gly Ser Ile Arg Tyr385 390 395 400Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu Val Leu Asp Tyr Leu Ser 405 410 415Ser Tyr Ile Asn Arg Arg Ile Gly Gly Gly Ser Gly Gly Gly Ser Gly 420 425 430Gly Gly Ser Asp Pro Thr Met Ala Asn Leu Leu Thr Val His Gln Asn 435 440 445Leu Pro Ala Leu Pro Val Asp Ala Thr Ser Asp Glu Val Arg Lys Asn 450 455 460Leu Met Asp Met Phe Arg Asp Arg Gln Ala Phe Ser Glu His Thr Trp465 470 475 480Lys Met Leu Leu Ser Val Cys Arg Ser Trp Ala Ala Trp Cys Lys Leu 485 490 495Asn Asn Arg Lys Trp Phe Pro Ala Glu Pro Glu Asp Val Arg Asp Tyr 500 505 510Leu Leu Tyr Leu Gln Ala Arg Gly Leu Ala Val Lys Thr Ile Gln Gln 515 520 525His Leu Gly Gln Leu Asn Met Leu His Arg Arg Ser Gly Leu Pro Arg 530 535 540Pro Ser Asp Ser Asn Ala Val Ser Leu Val Met Arg Arg Ile Arg Lys545 550 555 560Glu Asn Val Asp Ala Gly Glu Arg Ala Lys Gln Ala Leu Ala Phe Glu 565 570 575Arg Thr Asp Phe Asp Gln Val Arg Ser Leu Met Glu Asn Ser Asp Arg 580 585 590Cys Gln Asp Ile Arg Asn Leu Ala Phe Leu Gly Ile Ala Tyr Asn Thr 595 600 605Leu Leu Arg Ile Ala Glu Ile Ala Arg Ile Arg Val Lys Asp Ile Ser 610 615 620Arg Thr Asp Gly Gly Arg Met Leu Ile His Ile Gly Arg Thr Lys Thr625 630 635 640Leu Val Ser Thr Ala Gly Val Glu Lys Ala Leu Ser Leu Gly Val Thr 645 650 655Lys Leu Val Glu Arg Trp Ile Ser Val Ser Gly Val Ala Asp Asp Pro 660 665 670Asn Asn Tyr Leu Phe Cys Arg Val Arg Lys Asn Gly Val Ala Ala Pro 675 680 685Ser Ala Thr Ser Gln Leu Ser Thr Arg Ala Leu Glu Gly Ile Phe Glu 690 695 700Ala Thr His Arg Leu Ile Tyr Gly Ala Lys Asp Asp Ser Gly Gln Arg705 710 715 720Tyr Leu Ala Trp Ser Gly His Ser Ala Arg Val Gly Ala Ala Arg Asp 725 730 735Met Ala Arg Ala Gly Val Ser Ile Pro Glu Ile Met Gln Ala Gly Gly 740 745 750Trp Thr Asn Val Asn Ile Val Met Asn Tyr Ile Arg Asn Leu Asp Ser 755 760 765Glu Thr Gly Ala Met Val Arg Leu Leu Glu Asp Gly Asp 770 775 780 10 34 DNA Artificial Sequence Description of Artificial Sequence minimal wild-type FRT recombination site 10gaagttccta ttctctagaa agtataggaa cttc 34 11 781 PRT Artificial Sequence Description of Artificial Sequence CreFLP polypeptide, Cre from Bacteriophage P1 and FLP from Saccharomyces 11Met Ala Asn Leu Leu Thr Val His Gln Asn Leu Pro Ala Leu Pro Val 1 5 10 15Asp Ala Thr Ser Asp Glu Val Arg Lys Asn Leu Met Asp Met Phe Arg 20 25 30Asp Arg Gln Ala Phe Ser Glu His Thr Trp Lys Met Leu Leu Ser Val 35 40 45Cys Arg Ser Trp Ala Ala Trp Cys Lys Leu Asn Asn Arg Lys Trp Phe 50 55 60Pro Ala Glu Pro Glu Asp Val Arg Asp Tyr Leu Leu Tyr Leu Gln Ala 65 70 75 80Arg Gly Leu Ala Val Lys Thr Ile Gln Gln His Leu Gly Gln Leu Asn 85 90 95Met Leu His Arg Arg Ser Gly Leu Pro Arg Pro Ser Asp Ser Asn Ala 100 105 110Val Ser Leu Val Met Arg Arg Ile Arg Lys Glu Asn Val Asp Ala Gly 115 120 125Glu Arg Ala Lys Gln Ala Leu Ala Phe Glu Arg Thr Asp Phe Asp Gln 130 135 140Val Arg Ser Leu Met Glu Asn Ser Asp Arg Cys Gln Asp Ile Arg Asn145 150 155 160Leu Ala Phe Leu Gly Ile Ala Tyr Asn Thr Leu Leu Arg Ile Ala Glu 165 170 175Ile Ala Arg Ile Arg Val Lys Asp Ile Ser Arg Thr Asp Gly Gly Arg 180 185 190Met Leu Ile His Ile Gly Arg Thr Lys Thr Leu Val Ser Thr Ala Gly 195 200 205Val Glu Lys Ala Leu Ser Leu Gly Val Thr Lys Leu Val Glu Arg Trp 210 215 220Ile Ser Val Ser Gly Val Ala Asp Asp Pro Asn Asn Tyr Leu Phe Cys225 230 235 240Arg Val Arg Lys Asn Gly Val Ala Ala Pro Ser Ala Thr Ser Gln Leu 245 250 255Ser Thr Arg Ala Leu Glu Gly Ile Phe Glu Ala Thr His Arg Leu Ile 260 265 270Tyr Gly Ala Lys Asp Asp Ser Gly Gln Arg Tyr Leu Ala Trp Ser Gly 275 280 285His Ser Ala Arg Val Gly Ala Ala Arg Asp Met Ala Arg Ala Gly Val 290 295 300Ser Ile Pro Glu Ile Met Gln Ala Gly Gly Trp Thr Asn Val Asn Ile305 310 315 320Val Met Asn Tyr Ile Arg Asn Leu Asp Ser Glu Thr Gly Ala Met Val 325 330 335Arg Leu Leu Glu Asp Gly Asp Gly Gly Gly Ser Gly Gly Gly Ser Gly 340 345 350Gly Gly Ser Asp Pro Thr Met Pro Gln Phe Asp Ile Leu Cys Lys Thr 355 360 365Pro Pro Lys Val Leu Val Arg Gln Phe Val Glu Arg Phe Glu Arg Pro 370 375 380Ser Gly Glu Lys Ile Ala Leu Cys Ala Ala Glu Leu Thr Tyr Leu Cys385 390 395 400Trp Met Ile Thr His Asn Gly Thr Ala Ile Lys Arg Ala Thr Phe Met 405 410 415Ser Tyr Asn Thr Ile Ile Ser Asn Ser Leu Ser Leu Asp Ile Val Asn 420 425 430Lys Ser Leu Gln Phe Lys Tyr Lys Thr Gln Lys Ala Thr Ile Leu Glu 435 440 445Ala Ser Leu Lys Lys Leu Ile Pro Ala Trp Glu Phe Thr Ile Ile Pro 450 455 460Tyr Tyr Gly Gln Lys His Gln Ser Asp Ile Thr Asp Ile Val Ser Ser465 470 475 480Leu Gln Leu Gln Phe Glu Ser Ser Glu Glu Ala Asp Lys Gly Asn Ser 485 490 495His Ser Lys Lys Met Leu Lys Ala Leu Leu Ser Glu Gly Glu Ser Ile 500 505 510Trp Glu Ile Thr Glu Lys Ile Leu Asn Ser Phe Glu Tyr Thr Ser Arg 515 520 525Phe Thr Lys Thr Lys Thr Leu Tyr Gln Phe Leu Phe Leu Ala Thr Phe 530 535 540Ile Asn Cys Gly Arg Phe Ser Asp Ile Lys Asn Val Asp Pro Lys Ser545 550 555 560Phe Lys Leu Val Gln Asn Lys Tyr Leu Gly Val Ile Ile Gln Cys Leu 565 570 575Val Thr Glu Thr Lys Thr Ser Val Ser Arg His Ile Tyr Phe Phe Ser 580 585 590Ala Arg Gly Arg Ile Asp Pro Leu Val Tyr Leu Asp Glu Phe Leu Arg 595 600 605Asn Ser Glu Pro Val Leu Lys Arg Val Asn Arg Thr Gly Asn Ser Ser 610 615 620Ser Asn Lys Gln Glu Tyr Gln Leu Leu Lys Asp Asn Leu Val Arg Ser625 630 635 640Tyr Asn Lys Ala Leu Lys Lys Asn Ala Pro Tyr Ser Ile Phe Ala Ile 645 650 655Lys Asn Gly Pro Lys Ser His Ile Gly Arg His Leu Met Thr Ser Phe 660 665 670Leu Ser Met Lys Gly Leu Thr Glu Leu Thr Asn Val Val Gly Asn Trp 675 680 685Ser Asp Lys Arg Ala Ser Ala Val Ala Arg Thr Thr Tyr Thr His Gln 690 695 700Ile Thr Ala Ile Pro Asp His Tyr Phe Ala Leu Val Ser Arg Tyr Tyr705 710 715 720Ala Tyr Asp Pro Ile Ser Lys Glu Met Ile Ala Leu Lys Asp Glu Thr 725 730 735Asn Pro Ile Glu Glu Trp Gln His Ile Glu Gln Leu Lys Gly Ser Ala 740 745 750Glu Gly Ser Ile Arg Tyr Pro Ala Trp Asn Gly Ile Ile Ser Gln Glu 755 760 765Val Leu Asp Tyr Leu Ser Ser Tyr Ile Asn Arg Arg Ile 770 775 780

Claims

1. A recombinant protein comprising: a first site-specific recombinase fused in frame with a second site-specific recombinase.

2. A recombinant protein comprising a first site-specific recombinase or an active variant or an active fragment thereof fused in frame with a second site-specific recombinase or an active variant or an active fragment thereof, wherein said active variant and said active fragment retain site-specific recombinase activity.

3. The recombinant protein of claim 2, wherein said first and said second site-specific recombinases are members of the integrase family of recombinases or an active variant and an active fragment thereof, wherein said active variant and said active fragment retain site-specific recombinase activity.

4. The recombinant protein of claim 3, wherein said first and said second recombinases are selected from the group consisting of Cre, FLP and an active variant and an active fragment thereof, wherein said active variant and said active fragment retain site-specific recombinase activity.

5. The recombinant protein of claim 4, comprising the amino acid sequence of SEQ ID NO: 3 or an active variant or an active fragment thereof, wherein said active variant or said active fragment retains site-specific recombinase activity.

6. The recombinant protein of claim 4, wherein said first recombinase is Cre or an active variant or an active fragment thereof, and said second recombinase is FLP or an active variant or an active fragment thereof, wherein said active variant and said active fragment retain site-specific recombinase activity.

7. The recombinant protein of claim 6, wherein the Cre recombinase is moCre.

8. The recombinant protein of claim 6, wherein the FLP recombinase is FLPm.

9. The recombinant protein of claim 4, wherein said first recombinase is FLP or an active variant or an active fragment thereof, and said second recombinase is Cre or an active variant or an active fragment thereof, wherein said active variant and said active fragment retain site-specific recombinase activity.

10. The recombinant protein of claim 9, wherein the FLP recombinase is FLPm.

11. The recombinant protein of claim 9, wherein the Cre recombinase is moCre.

12. The recombinant protein of claim 4, comprising the amino acid sequence of SEQ ID NO:9 or an active variant or an active fragment thereof, wherein said active variant or said active fragment retains site-specific recombinase activity.

13. The recombinant protein of claim 1, wherein said first and said second site-specific recombinaes are selected from the group consisting of Cre and FLP.

14. A recombinant protein comprising the amino acid sequence of SEQ ID NO:3.

15. A recombinant protein comprising the amino acid sequence of SEQ ID NO: 9.